# Pfizer Inc: Form 10-Q for the period ended Apr 4, 2021

- Company: [Pfizer Inc](/companies/pfe.md) (CIK 78003)
- Form: 10-Q
- Filed: 2021-05-13
- Accepted by EDGAR: May 13, 2021, 11:32 ET
- Period: 2021-04-04
- Accession: 0000078003-21-000065
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/pfe-20210404.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-04-04.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-01-01 to 2021-04-04 | $14.58bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-01-01 to 2021-04-04 | $4.21bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2021-01-01 to 2021-04-04 | $2.78bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2021-01-01 to 2021-04-04 | $336.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-04-04 | $805.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-04-04 | $4.88bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-01-01 to 2021-04-04 | $0.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-01-01 to 2021-04-04 | $0.87 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-01-01 to 2021-04-04 | 5,662,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2021-01-01 to 2021-04-04 | $4.54bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2021-01-01 to 2021-04-04 | $554.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-04-04 | $1.77bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-04-04 | $39.53bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-04-04 | $158.82bn | us-gaap:Assets |
| Current liabilities | at 2021-04-04 | $26.65bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-04-04 | $89.95bn | us-gaap:Liabilities |
| Long-term debt | at 2021-04-04 | $35.35bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-04-04 | $3.68bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2021-04-04 | $416.0m | us-gaap:CommercialPaper |
| Shareholders' equity | at 2021-04-04 | $68.62bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/pfe-20210404.htm

Filed May 13, 2021.
Source: SEC EDGAR, the filing index for accession 0000078003-21-000065. Last ingested by Listed: Nov 12, 2026, 18:08 ET. No prices; not investment advice.
